# US 2025/0375475 A1 · Pharmaceutical composition and methods for modulating inflammation and oxidative stress

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375475 A1
- Document ID: US20250375475A1
- Status: Published application
- Kind: A1
- Application number: 18/739,957
- Filed: 2024-06-11
- Published: 2025-12-11
- Earliest claimed: 2024-06-11
- Assignees: Ism Biosciences LLC
- Applicants: Ism Biosciences LLC
- Inventors: Max Temnik; Oleksandr Balakin; Victor Gurin; Sergey Gurin
- Web page: https://patentgrep.com/patent/US20250375475A1

## CPC

- A61K 33/38: Silver; Compounds thereof
- A61K 31/01: Hydrocarbons
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/12: Ketones
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/405: Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/421: 1,3-Oxazoles, e.g. pemoline, trimethadione
- A61K 31/522: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/616: by carboxylic acids, e.g. acetylsalicylic acid
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61K 33/22: Boron compounds
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/26: Iron; Compounds thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61K 33/44: Elemental carbon, e.g. charcoal, carbon black
- A61K 38/063: {Glutathione}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are therapeutic compositions of matter for use in regulation of local and systemic inflammation and reduction of oxidative stress to enable discovery and development of more effective pharmaceutical agents, organic compounds, and other medicinal formulations.

## Claims

### Claim 1

A pharmaceutical composition for modulating inflammation and oxidative stress in mammals including at least one chemical element selected from H, Li, C, B, N, O, Mg, Si, S, K, Cl, Ca, V, Cr, Fe, Ni, Cu, Zn, Sr, Mo, Se, Ge, Ga, Br, Rb, Ag, and Ba, or a combination thereof, wherein said chemical elements are altered from their natural sample state so that 1H is enriched to exceed 99.985%, 6Li is enriched to exceed 10.06%, 12C is enriched to exceed 98.93%, 10B is enriched to exceed 21.01%, 14N is enriched to exceed 99.64%, 16O is enriched to exceed 99.81%, 17O is enriched to exceed 0.01%, 24Mg is enriched to exceed 80.01%, 25Mg is enriched to exceed 10.01%, 28Si is enriched to exceed 92.51%, 29Si is enriched to exceed 5.01%, 32S is enriched to exceed 95.03%, 33S is enriched to exceed 0.91%, 39K is enriched to exceed 93.51%, 35Cl is enriched to exceed 76.01%, 40Ca is enriched to exceed 96.95%, 42Ca is enriched to exceed 0.65%, 43Ca is enriched to exceed 0.65%, 50V is enriched to exceed 0.25%, 50Cr is enriched to exceed 4.25%, 52Cr is enriched to exceed 85.01%, 54Fe is enriched to exceed 5.85%, 56Fe is enriched to exceed 91.8%, 58Ni is enriched to exceed 68.10%, 60Ni is enriched to exceed 26.51%, 61Ni is enriched to exceed 1.12%, 63Cu is enriched to exceed 69.10%, 64Zn is enriched to exceed 58.61%, 66Zn is enriched to exceed 28.10%, 84Sr is enriched to exceed 0.60%, 92Mo is enriched to exceed 15.01%, 94Mo is enriched to exceed 9.25%, 95Mo is enriched to exceed 15.95%, 96Mo is enriched to exceed 16.69%, 74Se is enriched to exceed 0.90%, 76Se is enriched to exceed 9.25%, 77Se is enriched to exceed 7.65%, 78Se is enriched to exceed 23.81%, 70Ge is enriched to exceed 20.55%, 72Ge is enriched to exceed 27.57%, 73Ge is enriched to exceed 7.77%, 69Ga is enriched to exceed 64.11%, 79Br is enriched to exceed 50.70%, 85Rb is enriched to exceed 72.20%, 107Ag is enriched to exceed 51.61%, 130Ba is enriched to exceed 0.12%, 132Ba is enriched to exceed 0.12%, 134Ba is enriched to exceed 2.42%, 135Ba is enriched to exceed 6.60%, and/or 136Ba is enriched to exceed 7.86%.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, further including at least one of a carboxylic acid, a dicarboxylic acid, a sulfonic acid, a hydroxy acid, an amino acid, a fatty acid, an aromatic acid, a thiol, an enol, a phenol, a ribonucleic acid, or a combination thereof.

### Claim 3

The pharmaceutical composition of claim, 1 further including at least one of an enzyme, a peptide, a protein, an oligonucleotide, a nucleotide, an antibody, or a combination thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, further including at least one of a metal-ion binder, a protein nanocage, a chelating agent, a solute carrier, an enzyme inhibitor, a microsphere, a polymeric micelle, a liposome, a hybrid nanoparticle, a nanoparticle, a membrane-derived vesicle, a nanosome, a noisome, an adeno-associated virus, a metal conjugator, or a combination thereof.

### Claim 5

A method of modulating local and/or systemic inflammation in mammals including administering a therapeutically effective amount to a subject in need thereof of at least one isotope-specific chemical element selected from 6Li, 10B, 24Mg, 25Mg, 28Si, 29Si, 32S, 33S, 39K, 35Cl, 40Ca, 42Ca, 43Ca, 50V, 50Cr, 52Cr, 54Fe, 56Fe, 58Ni, 60Ni, 61Ni, 63Cu, 64Zn, 66Zn, 84Sr, 92Mo, 94Mo, 95Mo, 9% Mo, 74Se, 76Se, 77Se, 78Se, 70Ge, 72Ge, 73Ge, 69Ga, 79Br, 85Rb, 107Ag, 130Ba, 132Ba, 134Ba, 135Ba, and/or 136Ba present in elemental form, atomic form, colloidal substance form, in form of pharmaceutically acceptable compound, or in form of salt, or in combination of these forms, wherein 6Li is enriched to exceed 10.06%, 12C is enriched to exceed 98.93%, 10B is enriched to exceed 21.01%, 24Mg is enriched to exceed 80.01%, 25Mg is enriched to exceed 10.01%, 28Si is enriched to exceed 92.51%, 29Si is enriched to exceed 5.01%, 32S is enriched to exceed 95.03%, 33S is enriched to exceed 0.91%, 39K is enriched to exceed 93.51%, 35Cl is enriched to exceed 76.01%, 40Ca is enriched to exceed 96.95%, 42Ca is enriched to exceed 0.65%, 43Ca is enriched to exceed 0.65%, 50V is enriched to exceed 0.25%, 50Cr is enriched to exceed 4.25%, 52Cr is enriched to exceed 85.01%, 54Fe is enriched to exceed 5.85%, 56Fe is enriched to exceed 91.8%, 58Ni is enriched to exceed 68.10%, 60Ni is enriched to exceed 26.51%, 61Ni is enriched to exceed 1.12%, 63Cu is enriched to exceed 69.10%, 64Zn is enriched to exceed 58.61%, 66Zn is enriched to exceed 28.10%, 84Sr is enriched to exceed 0.60%, 92Mo is enriched to exceed 15.01%, 94Mo is enriched to exceed 9.25%, 95Mo is enriched to exceed 15.95%, 96Mo is enriched to exceed 16.69%, 74Se is enriched to exceed 0.90%, 76Se is enriched to exceed 9.25%, 77Se is enriched to exceed 7.65%, 78Se is enriched to exceed 23.81%, 70Ge is enriched to exceed 20.55%, 72Ge is enriched to exceed 27.57%, 73Ge is enriched to exceed 7.77%, 69Ga is enriched to exceed 64.11%, 79Br is enriched to exceed 50.70%, 85Rb is enriched to exceed 72.20%, 107Ag is enriched to exceed 51.61%, 130Ba is enriched to exceed 0.12%, 132Ba is enriched to exceed 0.12%, 134Ba is enriched to exceed 2.42%, 135Ba is enriched to exceed 6.60%, and/or 136Ba is enriched to exceed 7.86%.

### Claim 6 (depends on 5)

The method of claim 5, wherein the colloidal substance form includes at least one of sanitized water, distilled water, demineralized water, ionized water, deuterium-depleted water, pharmaceutically acceptable oil, natural polymer, synthetic polymer, carboxymethylcellulose, methylcellulose, hydroxypropyl cellulose, and/or a combination thereof.

### Claim 7 (depends on 5)

The method of claim 5, wherein the pharmaceutically acceptable compound includes at least one non-steroidal anti-inflammatory drug selected from ibuprofen, aspirin, naproxen, diclofenac, etodolac, fenoprofen, flurbiprofen, indomethacin, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, a COX-2 inhibitor, or a combination thereof.

### Claim 8 (depends on 5)

The method of claim 5, wherein the pharmaceutically acceptable compound includes at least one of an enzyme inhibitor, ATP-binding agent, solute-linked carrier, organic anion or cation, or non-organic anion or cation, a polymeric nanocarrier, a metal-organic framework, a lipid-based nanoparticle, a dendrimer, a nanostructured lipid carrier, a carbon nanotube, or a combination thereof.

### Claim 9 (depends on 5)

The method of claim 5, wherein the salt includes at least one of an organic salt, an inorganic salt, or a chelating agent, or a combination thereof.

### Claim 10

A method of reducing oxidative stress including administering a therapeutically effective amount to a subject in need thereof of at least one isotope-specific chemical element selected from 6Li, 12C, 10B, 24Mg, 25Mg, 28Si, 29Si, 32S, 33S, 39K, 35Cl, 40Ca, 42Ca, 43Ca, 50V, 50Cr, 52Cr, 54Fe, 56Fe, 58Ni, 60Ni, 61Ni, 63Cu, 64Zn, 66Zn, 84Sr, 92Mo, 94Mo, 95Mo, 96Mo, 74Se, 76Se, 77Se, 78Se, 70Ge, 72Ge, 73Ge, 69Ga, 79Br, 85Rb, 107Ag, 130Ba, 132Ba, 134Ba, 135Ba, and/or 136Ba, present in elemental form, atomic form, colloidal substance form, in form of pharmaceutically acceptable compound, or in form of a salt, wherein 6Li is enriched to exceed 10.06%, 12C is enriched to exceed 98.93%, 10B is enriched to exceed 21.01%, 24Mg is enriched to exceed 80.01%, 25Mg is enriched to exceed 10.01%, 28Si is enriched to exceed 92.51%, 29Si is enriched to exceed 5.01%, 32S is enriched to exceed 95.03%, 33S is enriched to exceed 0.91%, 39K is enriched to exceed 93.51%, 35Cl is enriched to exceed 76.01%, 40Ca is enriched to exceed 96.95%, 42Ca is enriched to exceed 0.65%, 43Ca is enriched to exceed 0.65%, 50V is enriched to exceed 0.25%, 50Cr is enriched to exceed 4.25%, 52Cr is enriched to exceed 85.01%, 54Fe is enriched to exceed 5.85%, 56Fe is enriched to exceed 91.8%, 58Ni is enriched to exceed 68.10%, 60Ni is enriched to exceed 26.51%, 61Ni is enriched to exceed 1.12%, 63Cu is enriched to exceed 69.10%, 64Zn is enriched to exceed 58.61%, 66Zn is enriched to exceed 28.10%, 84Sr is enriched to exceed 0.60%, 92Mo is enriched to exceed 15.01%, 94Mo is enriched to exceed 9.25%, 95Mo is enriched to exceed 15.95%, 96Mo is enriched to exceed 16.69%, 74Se is enriched to exceed 0.90%, 76Se is enriched to exceed 9.25%, 77Se is enriched to exceed 7.65%, 78Se is enriched to exceed 23.81%, 70Ge is enriched to exceed 20.55%, 72Ge is enriched to exceed 27.57%, 73Ge is enriched to exceed 7.77%, 69Ga is enriched to exceed 64.11%, 79Br is enriched to exceed 50.70%, 85Rb is enriched to exceed 72.20%, 107Ag is enriched to exceed 51.61%, 130Ba is enriched to exceed 0.12%, 132Ba is enriched to exceed 0.12%, 134Ba is enriched to exceed 2.42%, 135Ba is enriched to exceed 6.60%, and/or 136Ba is enriched to exceed 7.86%.

### Claim 11 (depends on 10)

The method of claim 10, wherein the colloidal substance further includes at least one of ozonized water, distilled water, demineralized water, ionized water, and/or deuterium-depleted water, or a combination thereof.

### Claim 12 (depends on 10)

The method of claim 10 further includes administering at least one of paracetamol, resveratrol, beta-carotene, vitamin B, vitamin C, vitamin D, vitamin E, glutathione, coenzyme Q10, caffein, and/or or a combination thereof.

### Claim 13 (depends on 10)

The method of claim 10 further includes administering at least one of histidine, arginine, leucine, isoleucine, lysine, methionine, phenylalanine, tyrosine, threonine, tryptophan, valine, or a combination thereof.

### Claim 14 (depends on 10)

The method of claim 10 further includes administering at least one of a proteinogenic amino acid or nonessential amino acid or a combination thereof.
